Compare GNLN & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNLN | PPCB |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | Australia |
| Employees | N/A | 2 |
| Industry | Durable Goods | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.6M |
| IPO Year | 2019 | N/A |
| Metric | GNLN | PPCB |
|---|---|---|
| Price | $0.31 | $0.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 284.6K | ★ 1.2M |
| Earning Date | 05-14-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,275,000.00 | N/A |
| Revenue This Year | $1,541.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.01 | $0.10 |
| 52 Week High | $7.73 | $10.69 |
| Indicator | GNLN | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 28.41 | 34.60 |
| Support Level | N/A | N/A |
| Resistance Level | $0.89 | $0.40 |
| Average True Range (ATR) | 0.12 | 0.01 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.01 | 40.50 |
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.